Kotecka-Blicharz Agnieszka, Hasse-Lazar Kornelia, Handkiewicz-Junak Daria, Gawlik Tomasz, Pawlaczek Agnieszka, Oczko-Wojciechowska Małgorzata, Michalik Barbara, Szpak-Ulczok Sylwia, Krajewska Jolanta, Jurecka-Lubieniecka Beata, Jarząb Barbara
Department of Nuclear Medicine and Endocrine Oncology,, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeża Armii Krajowej 15, 44-101 Gliwice, Poland.
Endokrynol Pol. 2018;69(3):246-251. doi: 10.5603/EP.a2018.0024. Epub 2018 Apr 12.
Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL).
18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively. Clinical indications for the treatment included progressive disease or massive tissue involvement independently from disease progression. Tumor response for the first time was assessed 3 months after the last treatment according to Response Evaluation Criteria in Solid Tumors criteria and by 131-I MIBG scans.
The mean single dose used was 7.25 GBq (196 mCi) and mean cumulative dose 33.08 GBq ( 894 mCi). In 2 (11%) patients complete tumor response was achieved. In 1 (6%) patient partial response was obtained. In 13 (72%) patients stable disease was observed. In 2 (11%) patients progression was diagnosed three months after treatment discontinuation. In the whole studied group the progression free survival time was 85 months and overall 5-year survival was 87%.
Radionuclide treatment with use of 131-I MIBG may be effective form of palliative treatment for patients with inoperative neoplasm spread, progressive disease or patients requiring alleviation of symptoms. < p > < /p >.
嗜铬细胞瘤和副神经节瘤是起源于肾上腺髓质或副神经节嗜铬细胞的罕见肿瘤。它们通常为良性，但其中10% - 35%会表现出恶性行为。本研究的目的是评估131碘间碘苄胍（131-I MIBG）治疗恶性嗜铬细胞瘤/副神经节瘤患者（MPPGL）的疗效和安全性。
本研究纳入了18例患者（7例女性和11例男性）。在2002年至2016年期间，他们因MPPGL接受了131-I MIBG治疗，并对其医疗数据进行了回顾性分析。治疗的临床指征包括疾病进展或大量组织受累，与疾病进展无关。根据实体瘤疗效评价标准，在最后一次治疗3个月后首次评估肿瘤反应，并通过131-I MIBG扫描进行评估。
使用的平均单次剂量为7.25GBq（196mCi），平均累积剂量为33.08GBq（894mCi）。2例（11%）患者实现了肿瘤完全缓解。1例（6%）患者获得部分缓解。13例（72%）患者病情稳定。2例（11%）患者在停止治疗3个月后被诊断为疾病进展。在整个研究组中，无进展生存期为85个月，总体5年生存率为87%。
使用131-I MIBG进行放射性核素治疗可能是对无法手术切除的肿瘤转移、疾病进展或需要缓解症状的患者进行姑息治疗的有效方式。
